ISFIYA, Israel and CHALFONT ST. GILES, England, May 9, 2017 /PRNewswire/ -- Check-Cap Ltd.
(NASDAQ: CHEK, CHEKW), a clinical-stage company engaged in the
development of an ingestible capsule for preparation-free,
colorectal cancer screening and GE Healthcare (NYSE: GE) today
announced the companies have successfully achieved the initial
milestone in their ongoing collaboration to develop high-volume,
X-ray capsule manufacturing capabilities. Specifically, X-ray
sources produced at GE Healthcare using a customized manufacturing
method passed all tests required to ensure compliance with
C-Scan® system specifications.
"We are very excited to have achieved success in the first
critical phase of our collaboration with GE Healthcare, where we
demonstrated the capability of our process to manufacture X-ray
sources for the C-Scan® system," said Bill
Densel, CEO of Check-Cap. "We look forward to moving ahead
with the development and validation of scalable production and
integration processes that can provide capsules for future U.S.
clinical trials and commercialization."
Colorectal cancer is the second leading cause of cancer death in
the U.S., with an estimated 135,000 diagnoses and 50,000 deaths in
2017[1]. Despite compelling evidence that
screening can detect colorectal cancer and precancerous polyps,
nearly one-third of the recommended adult population has never been
screened. The C-Scan® system is designed to improve the patient
experience with screening by eliminating many unattractive
requirements, such as bowel preparation, fasting, and sedation.
"The results of this critical phase of the collaboration are
incredibly exciting for patients and the future prevention of
colorectal cancer," said Emmanuel
Ligner, General Manager of Core Imaging for GE Healthcare
Life Sciences. "GE Healthcare will continue its collaboration with
Check-Cap using our expertise in radiopharmaceutical and device
manufacturing to bring the C-Scan® system to clinicians and
patients."
1 "Key Statistics for Colorectal Cancer,"
American Cancer
Society, https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html
About Check-Cap
Check-Cap is a clinical-stage medical diagnostics company
developing C-Scan®, the first capsule-based system for
preparation-free colorectal cancer screening.
Utilizing innovative ultra-low dose X-ray and wireless
communication technologies, the capsule generates information on
the contours of the inside of the colon as it passes naturally.
This information is used to create a 3D map of the colon,
which allows physicians to look for polyps and other abnormalities.
Designed to improve the patient experience and increase the
willingness of individuals to participate in recommended colorectal
cancer screening, C-Scan® removes many frequently-cited barriers,
such as laxative bowel preparation, invasiveness and sedation. The
C-Scan® system is currently not cleared for marketing in any
jurisdiction.
About GE Healthcare
GE Healthcare provides transformational medical technologies and
services to meet the demand for increased access, enhanced quality
and more affordable healthcare around the world. GE (NYSE:
GE) works on things that matter - great people and technologies
taking on tough challenges. From medical imaging, software &
IT, patient monitoring and diagnostics to drug discovery,
biopharmaceutical manufacturing technologies and performance
improvement solutions, GE Healthcare helps medical professionals
deliver great healthcare to their patients. For more information
about GE Healthcare, visit our website
at http://www.gehealthcare.com.
Legal Notice Regarding Forward-Looking
Statements
This press release contains "forward-looking statements."
Words such as "may," "should," "could," "would," "predicts,"
"potential," "continue," "expects," "anticipates," "future,"
"intends," "plans," "believes," "estimates," and similar
expressions, as well as statements in future tense, often signify
forward-looking statements. Forward-looking statements should not
be read as a guarantee of future performance or results and may not
be accurate indications of when such performance or results will be
achieved. Forward-looking statements are based on information that
the Company has when those statements are made or management's good
faith belief as of that time with respect to future events, and are
subject to risks and uncertainties that could cause actual
performance or results to differ materially from those expressed in
or suggested by the forward-looking statements. For a discussion of
these and other risks that could cause such differences and that
may affect the realization of forward-looking statements, please
refer to the "Special Note On Forward-looking Statements" and "Risk
Factors" in the Company's Annual Report on Form 20-F and other
filings with the Securities and Exchange Commission (SEC).
Investors and security holders are urged to read these documents
free of charge on the SEC's web site
at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
CONTACT:
Investors
David Carey
Lazar Partners Ltd.
+1-212-867-1768
dcarey@lazarpartners.com
Vivian Cervantes
PCG Advisory
+1-212-554-5482
vivian@pcgadvisory.com
Media
Erich Sandoval or Rob Sawyer
Lazar Partners Ltd.
+1-213-908-6226 or +1-212-843-0209
esandoval@lazarpartners.com
rsawyer@lazarpartners.com
GE Healthcare
Mia Mallen
Communications
+1-857-260-4055
mia.mallen@ge.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/check-cap-and-ge-healthcare-achieve-development-milestone-in-high-volume-x-ray-capsule-manufacturing-collaboration-300454037.html
SOURCE Check-Cap Ltd.; GE Healthcare